723286-86-0

Usage

InChI:InChI=1/C7H5F3N4/c1-4-2-11-3-5-12-13-6(14(4)5)7(8,9)10/h2-3H,1H3

Upstream product

• 19848-57-8 2-hydrazino-6-methylpyrazine 
• 407-25-0 trifluoroacetic anhydride 
• 1447800-66-9 2-(1-bromo-2,2,2-trifluoroethylidene)-1-(6-methylpyridin-2-yl)hydrazine 
• 1447800-63-6 2-(2,2,2-trifluoroethylidene)-1-(6-methylpyridin-2-yl)hydrazine 
• 5315-24-2 1-(6-methylpyridin-2-yl)hydrazine 
• 38557-71-0 2-chloro-6-methylpyrazine 

Downstream Products

• 723286-87-1 5-methyl-3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine 

Relevant academic research and scientific papers

QUINOLINE DERIVATIVES AS SMO INHIBITORS

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Exploring the unexplored practical and alternative synthesis of 3-(trifluoromethyl)-triazolopiperazine the key intermediate for Sitagliptin

The practical synthesis of 3-(trifluoromethyl)-triazolopiperazine the key intermediate of Sitagliptin and 3-(trifluoromethyl)-triazolopyridine was carried out employing industrially feasible transformations. The other advantage of this method is the new environment friendly approach to synthesize triazolopiperazine and triazolopyridines by eliminating the commonly used trifluoroacetic anhydride and polyphosphoric acid.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing subsituted triazolopiperazines

A series of β-aminoamides bearing triazolopiperazines have been discovered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive structure-activity relationship (SAR) studies around the triazolopiperazine moiety.

3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.